文献速递白血病

半剂量维奈克拉联合减量HA方案诱导治疗初诊急性髓系白血病的疗效分析

[Analysis of the efficacy of half-dose venetoclax combined with reduced-dose HA regimen in the induction therapy of acute myeloid leukemia].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2026-01-01

该研究回顾性分析了33例接受HAV方案(半剂量维奈克拉联合高三尖杉酯碱和阿糖胞苷)诱导治疗的初诊急性髓系白血病患者。结果显示总有效率90.9%,完全缓解率87.9%,诱导期间无死亡,预估3年总生存率68.2%。HAV方案对初诊AML患者高效且安全。

要点

  • HAV方案诱导初诊AML的完全缓解率达87.9%。
  • 诱导治疗期间无患者死亡,中性粒细胞和血小板中位恢复时间均为10天。
  • 预估3年总生存率为68.2%(95% CI:59.7%~76.7%)。

核心结论

  • HAV方案是一种对初诊AML患者高效且安全的诱导治疗方案。

研究设计与样本

  • 回顾性分析2020年6月至2023年4月期间接受HAV方案诱导治疗的33例初诊AML患者的临床数据。
  • HAV方案为:维奈克拉第0天100 mg,第1~14天200 mg口服;高三尖杉酯碱2 mg/m²第3~9天静脉滴注;阿糖胞苷50 mg/m²第3~9天静脉滴注。
  • 33例患者中男性占36.4%(12/33),中位年龄60(14~67)岁。

主要发现

  • 诱导治疗1个周期后总有效率为90.9%,完全缓解(CR)率为87.9%。
  • CR患者中79.3%达到可测量残留病(MRD)阴性的CR。
  • 诱导治疗期间无患者死亡。
  • 中性粒细胞恢复(≥1.0×10⁹/L)和血小板恢复(≥30×10⁹/L)的中位时间分别为10(5~12)天和10(3~13)天。
  • 截至2024年10月30日,预估3年总生存率、无事件生存率和无病生存率分别为68.2%(95% CI:59.7%~76.7%)、66.7%(95% CI:58.5%~74.9%)和73.6%(95% CI:65.6%~81.6%)。

临床怎么用

  • HAV方案可作为初诊AML患者的一种诱导治疗选择,需注意其回顾性研究背景。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We retrospectively analyzed clinical data on newly diagnosed acute myeloid leukemia (AML) patients who received HAV treatment between June 2020 and April 2023. The HAV regimen includes venetoclax at 100 mg on day 0 and 200 mg from day 1 to 14, administered orally; homoharringtonine at 2 mg/m(2) from day 3 to 9, given by intravenous infusion; and cytarabine at 50 mg/m(2) from day 3 to 9, also administered by intravenous infusion. Among 33 patients, 36.4% (12/33) were male, with a median age of 60 years (range, 14-67 years). The overall response rate after one cycle of induction therapy was 90.9%, and the complete response (CR) rate was 87.9%. Among the patients, 79.3% achieved CR with measurable residual disease negativity. No patient died during induction therapy. The median recovery times of neutrophils (≥1.0×10(9)/L) and platelets (≥30×10(9)/L) were 10 (5-12) days and 10 (3-13) days, respectively. Until October 30, 2024, the estimated 3-year overall survival rate, event-free survival rate, and disease-free survival rate were 68.2% (95% CI: 59.7% -76.7% ), 66.7% (95% CI: 58.5% -74.9% ), and 73.6% (95% CI: 65.6% -81.6% ), respectively. HAV is a highly effective and safe induction therapy regimen for patients with newly diagnosed AML. 回顾性分析2020年6月至2023年4月期间接受HAV方案诱导治疗的33例初诊急性髓系白血病(AML)患者的临床数据。HAV方案具体为维奈克拉(Ven)第0天100 mg;第1~14天200 mg,口服;高三尖杉酯碱(HHT)2 mg/m(2),第3~9天,静脉滴注;阿糖胞苷50 mg/m(2),第3~9天,静脉滴注。33例患者中男性占36.4%(12/33),中位年龄为60(14~67)岁。诱导治疗1个周期后的总有效率为90.9%,完全缓解(CR)率为87.9%。CR患者中79.3%达到可测量残留病(MRD)阴性的CR。诱导治疗期间无患者死亡。中性粒细胞恢复(≥1.0×10(9)/L)和血小板恢复(≥30×10(9)/L)的中位时间分别为10(5~12)d和10(3~13)d。截至2024年10月30日,预估3年总生存率、无事件生存率和无病生存率分别为68.2%(95% CI:59.7%~76.7%)、66.7%(95% CI:58.5%~74.9%)和73.6%(95% CI:65.6%~81.6%)。HAV是一种对初诊AML患者高效且安全的诱导治疗方案。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Yan ZS, Suo XH, Bai GC, et al. [Analysis of the efficacy of half-dose venetoclax combined with reduced-dose HA regimen in the induction therapy of acute myeloid leukemia]. Zhonghua Xue Ye Xue Za Zhi. 2026. PMID: 42161662. doi:10.3760/cma.j.cn121090-20250516-00232

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。